CellBxHealth has entered a collaboration with AdventHealth for the use of its Parsortix circulating tumour cell platform in two multi‑centre studies designed to advance minimally invasive cancer monitoring.
AdventHealth is one of the largest faith‑based health systems in the US, providing a broad clinical network for real‑world evaluation.
The studies, ACTION and SUNRISE, will isolate and analyse circulating tumour cells from blood samples to assess treatment response and tumour biology without the need for invasive biopsies.
Researchers will use the platform for both enumeration and PD‑L1 characterisation, offering real‑time insight into how tumours evolve during therapy.
ACTION is an NIH‑funded trial enrolling 219 patients to examine how different levels of aerobic exercise influence chemotherapy tolerability in colon cancer.
SUNRISE, due to begin in July 2026, will recruit 120 patients with gastrointestinal and lung cancers to evaluate whether remotely delivered exercise interventions can improve chemotherapy tolerance and quality of life.
Across both studies, CTC analysis will serve as a novel correlative endpoint, supporting efforts to understand how behavioural interventions and treatment regimens shape tumour dynamics.
A key aim is to bring advanced cancer monitoring closer to patients’ homes. With most US cancer care delivered in community settings, combining remote interventions with simple blood‑based diagnostics could reduce travel, lessen patient burden and enable continuous monitoring regardless of geography.
The approach also seeks to address entrenched health inequalities that limit access to specialist oncology services.
AdventHealth’s national footprint provides a strong platform to scale these technologies in routine practice. For CellBxHealth, the collaboration represents a significant commercial opportunity to validate and expand adoption of the Parsortix platform across a major integrated health system, supporting broader use of liquid biopsy in everyday oncology care.
